骨髓干细胞对终末期肝病治疗的临床研究进展  

Clinical use of bone-marrow stem cell therapy for end-stage liver disease

作　　者：郑林华[1] 韩英[1] 

机构地区：[1]第四军医大学西京消化病医院,西安710032

出　　处：《中华细胞与干细胞杂志（电子版）》2015年第2期53-57,共5页Chinese Journal of Cell and Stem Cell（Electronic Edition）

摘　　要：目前利用骨髓干细胞(BMSC)治疗终末期肝病越来越受到关注,且大多数研究表明BMSC能有效改善患者的肝功能,然而其具体机制尚不清楚。目前采集BMSC的方法有多种,比如可以采用粒细胞集落刺激因子(G-CSF)动员BMSC至外周血,然后通过外周血采集干细胞,或者直接从骨髓中采集干细胞。BMSC主要含骨髓造血干细胞(HSC)和间充质干细胞(MSC),哪种干细胞是促进肝功能恢复的主要细胞目前仍有争论。因此,本文将从临床研究总结BMSC在终末期肝病治疗中的研究进展。At present, the use of bone marrow-derived stem cell （BMSC） in the treatment of end-stage liver disease has received more and more attention. And most of the researches suggest that BMSC could improve liver function of the patients with end-stage liver disease. However, the underlining mechanisms are still unknown. There are several methods to collect BMSC, for example, BMSC could be mobilized by granulocyte-colony stimulating factor （G-CSF） into the peripheral blood and subsequent collected through the peripheral blood. Or we can collect BMSC direct through bone marrow. BMSC include mainly hematopoietic stem cells （HSC） and mesenchymal stem cells （MSC）. But there is much debate concerning which kind of stem cells contributes more to hepatic improvement. Thus, this review will summarize the clinical research progress of BMSC in the treatment of end-stage liver diseases.

关 键 词：肝病 间质干细胞 骨髓 粒细胞集落刺激因子 

分 类 号：R575.3[医药卫生—消化系统] R457.7[医药卫生—内科学]